Biosimilar monoclonal antibodies

Biosimilars and biobetters industry is likely to become a lot more dynamic and strategic than we’ve seen with small molecule generics; there will begin to become a premium on flexibility and willingness to take chances in an ever-shifting competitive and regulatory environment. The approval of the first biosimilar in the US is expected to save the healthcare industry and patients $5.7 billion over the next decade. The US biosimilars market is expected to reach $2 billion by 2018 and with the first biosimilar approved recently in America, this is an exciting time for the biosimilar field with approval in the US expected to increase during the next ten years. The regulatory landscape is evolving rapidly so it is important to understand the developments in the biosimilar guideline framework and the cohesion in legislation between the US and Europe. Key factors driving market growth include patent expiries of key biological drugs, cost containment measures from governments, aging population, and supporting legislations. The recent establishment of regulatory guidelines for biosimilars in the US is expected to add further momentum to the growth of the global biosimilars market. Increasing pressure from governments and insurers for greater biologic competition, there exists an incredible opportunity for biosimilar producers to capitalise on what is set to become the fastest growing sector of the pharmaceutical industry. 

Advice from experts was clear; biosimilar companies need to focus on products that see IP [intellectual property] begin to expire beyond 2020, the so-called third wave of biosimilar opportunity.

  • Biosimilars and Non-Originator Biologics
  • Biosimilar Regime
  • Use of Autologous IL-1ra and Other Cytokines in Orthopedics
  • Technological Platform for Innovative and Biosimilar Antibodies
  • Biosimilars and Non-Originator Biologics
  • Novel Cell-Based Bioassays for Analysis of mAb Fc Effector and Immune Checkpoint

Related Conference of Biosimilar monoclonal antibodies

Zurich Hilton Airport Hotel, September 13-14, 2018

11th Annual Congress on Immunology & Immunotechnology

Zurich, Switzerland
September 17-18, 2018

3rd International Conference on Tumor & Cancer Immunology and Immunotherapy

San Diego, California, USA
September 17-18, 2018

3rd International Conference on Tumor & Cancer Immunology and Immunotherapy

San Diego, California, USA
October 19-20, 2018

10th World Congress and Expo on Immunology

New York, USA
October 29-30, 2018

6th International Conference on HIV/AIDS, STDs and STIs

San Francisco, USA
November 22-23, 2018

World Conference on Vaccine and Immunology

Bucharest, Romania
November 26-27, 2018

3rd International Conference on Autoimmunity

Dublin, Ireland
December 05-06, 2018

Global Meet on Immunology, Hematology and Molecular Biology

Portugal, Lisbon
December 06-08, 2018

Annual Congress on Antibiotics and Antimicrobial Resistance

Amsterdam, Netherlands
March 04-05, 2019

10th Molecular Immunology & Immunogenetics Congress

Barcelona, Spain
March 18-19, 2019

11th Global Summit on Immunology and Cell Biology

Sydney, Australia
June 13-14, 2019 |

10th European Immunology Conference

Berlin, Germany
July 29-30 2019

6th International Conference on Parasitology & Microbiology

Amsterdam, Netherlands

Biosimilar monoclonal antibodies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in